Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia

Immunologic Research

Volumn 64, Issue 2, 2016, Pages 604-609

  Qiao, Jianlin ^a,b   Liu, Yun ^a   Li, Depeng ^a   Wu, Yulu ^a,b   Li, Xiaoqian ^a,b   Yao, Yao ^a,b   Niu, Mingshan ^a,b   Fu, Chunling ^a,b   Li, Hongchun ^a   Ma, Ping ^a   Li, Zhenyu ^a   Xu, Kailin ^a,b   Zeng, Lingyu ^a,b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Bone Marrow Stem Cell   (China)

Author keywords

Apoptosis; Bax; Bcl xL; Caspase 3; Immune thrombocytopenia

Indexed keywords

CASPASE 3; MESSENGER RNA; PHOSPHATIDYLSERINE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BCL X;

ADULT; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; UPREGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MITOCHONDRION; YOUNG ADULT;

ADULT; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOOD PLATELETS; CASPASE 3; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 84961151538     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8760-z     Document Type: Article

References (27)

1. Neunert CE. Current management of immune thrombocytopenia. Hematol Am Soc Hematol Educ Progr. 2013;2013:276–82.
2. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Med. 2014;43:e49–59.
3. McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163:10–23.
4. + T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115:1247–53.
5. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
6. von Gunten S, Wehrli M, Simon HU. Cell death in immune thrombocytopenia: novel insights and perspectives. Semin Hematol. 2013;50(Suppl 1):S109–15.
7. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173–86.
8. White MJ, Kile BT. Apoptotic processes in megakaryocytes and platelets. Semin Hematol. 2010;47:227–34.
9. Qi B, Hardwick JM. A Bcl-xL timer sets platelet life span. Cell. 2007;128:1035–6.
10. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663–74.
11. Qiao J, Liu Y, Li X, Xia Y, Wu Y, Li D, et al. Elevated expression of NLRP3 in patients with immune thrombocytopenia. Immunol Res 2015.
12. Qiao J, Liu Y, Wu Y, Li X, Zhu F, Xia Y, et al. Aberrant expression of RUNX3 in patients with immune thrombocytopenia. Int Immunopharmacol. 2015;28:252–6.
13. Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW. Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol. 2008;6:e147.
14. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46:497–510.
15. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.
16. Walters J, Pop C, Scott FL, Drag M, Swartz P, Mattos C, et al. A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J. 2009;424:335–45.
17. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264–74.
18. Leytin V. Apoptosis in the anucleate platelet. Blood Rev. 2012;26:51–63.
19. Leytin V, Allen DJ, Lyubimov E, Freedman J. Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. Br J Haematol. 2007;136:762–4.
20. Leytin V, Allen DJ, Mykhaylov S, Mis L, Lyubimov EV, Garvey B, et al. Pathologic high shear stress induces apoptosis events in human platelets. Biochem Biophys Res Commun. 2004;320:303–10.
21. Leytin V, Allen DJ, Mutlu A, Mykhaylov S, Lyubimov E, Freedman J. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol. 2008;142:494–7.
22. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–8.
23. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ. 2008;15:243–50.
24. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002;88:186–93.
25. Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. 2006;34:879–87.
26. Winkler J, Kroiss S, Rand ML, Azzouzi I, Annie Bang KW, Speer O, et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol. 2012;156:508–15.
27. Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 2014;21:206–15.